<div id="readability-page-1"><p>TD Cowen analyst Tara Bancroft has maintained their neutral  stance on <span>FATE</span> stock, giving a Hold rating today.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Tara Bancroft has given his Hold rating due to a combination of factors, balancing promising clinical momentum with remaining execution and regulatory risks. FT819’s progress in autoimmune diseases, including accelerated enrollment, outpatient feasibility, and supportive designations such as RMAT and CDRP, highlights a differentiated profile and underpins expectations for a potentially pivotal lupus nephritis study in the second half of 2026.</p> <p>At the same time, the investment case remains highly dependent on successful advancement of early-stage programs and timely initiation of the registrational-intent trial, which introduces uncertainty around development, regulatory outcomes, and commercialization timelines. While the extended cash runway into 2028 and a catalyst-rich pipeline are positives, Tara Bancroft views the current share price as appropriately reflecting these opportunities and risks, supporting a neutral, Hold stance rather than a more aggressive rating.</p> <p>According to TipRanks, Bancroft is a 5-star analyst with an average return of <span>31.0%</span> and a 53.95% success rate. Bancroft covers the Healthcare sector, focusing on stocks such as Geron, Ocular Therapeutix, and Day One Biopharmaceuticals.</p> </div>

FATE

IBBQ

SBIO

LABU

<p>TD Cowen analyst Tara Bancroft has reiterated a Hold rating on FATE stock, citing a balance of promising clinical momentum for FT819 in autoimmune diseases against execution and regulatory risks. Key factors include accelerated enrollment and supportive designations, with expectations for a pivotal lupus nephritis study in 2026. Despite a positive cash runway and a catalyst-rich pipeline, Bancroft believes the current share price reflects these opportunities and risks, justifying a neutral stance. Bancroft is a 5-star analyst with a 31.0% average return and 53.95% success rate in the Healthcare sector.</p>

Tip Ranks

Fate Therap

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

Toronto Dominion Bank

Geron

Ocular Therap

Day One Biopharmaceuticals

Tara Bancroft Reiterates Hold Rating as FT819’s Autoimmune Momentum Offsets Early-Stage, Regulatory and Execution Risks